17969-48-1

Usage

Uses

Used in Pharmaceutical Industry:
2-[4-(4-FLUOROPHENYL)-1,3-THIAZOL-2-YL]ACETONITRILE is used as a potential pharmaceutical compound for its unique molecular structure that may offer therapeutic benefits. The presence of the thiazole ring and the 4-fluorophenyl group could contribute to its interaction with biological targets, making it a candidate for drug development.
Used in Chemical Research:
2-[4-(4-FLUOROPHENYL)-1,3-THIAZOL-2-YL]ACETONITRILE is used as a research chemical for studying its properties and potential applications. 2-[4-(4-FLUOROPHENYL)-1,3-THIAZOL-2-YL]ACETONITRILE's structure may provide insights into the development of new materials or processes in the field of organic chemistry.
Used in Material Science:
2-[4-(4-FLUOROPHENYL)-1,3-THIAZOL-2-YL]ACETONITRILE is used as a component in the development of new materials, potentially due to its unique chemical structure. Its properties may be harnessed to create novel materials with specific characteristics for use in various industries.

InChI:InChI=1/C11H7ClN2S/c12-9-3-1-8(2-4-9)10-7-15-11(14-10)5-6-13/h1-4,7H,5H2

Upstream product

• 7357-70-2 Cyanothioacetamide 
• 536-38-9 4-chlorobenzoylmethyl bromide 

Downstream Products

• 425413-77-0 4-chloro-2-[4-(4-chloro-phenyl)-3H-thiazol-2-ylidene]-3-oxo-butyronitrile 
• 1046768-35-7 (E)-2-[4-(4-chlorophenyl)thiazol-2-yl-2-[1-ethylpyridin-2(1H)-ylidene]acetonitrile] 
• 1046768-32-4 (E)-2-[4-(4-chlorophenyl)thiazol-2-yl-2-[1-methylpyridin-2(1H)-ylidene]acetonitrile] 
• 1174555-34-0 C₅H₁₁N*C₂₀H₁₇ClN₂O₂S 
• 1030102-92-1 C₂₂H₁₅ClN₂O₃S 
• 1032228-77-5 C₁₇H₁₂ClN₅S 
• 1431771-50-4 (E)-2-[4-(4-chlorophenyl)thiazol-2-yl]-2-[1-(2-ethoxy-2-oxoethyl)pyridin-2(1H)-ylidene]acetonitrile 
• 1431771-52-6 2-amino-1-(4-chlorophenylthiazol-2-yl)-3-ethoxycarbonyl-indolizine 

Relevant academic research and scientific papers

Discovery and Optimization of 2 H-1λ2-Pyridin-2-one Inhibitors of Mutant Isocitrate Dehydrogenase 1 for the Treatment of Cancer

Neomorphic mutations in isocitrate dehydrogenase 1 (IDH1) are oncogenic for a number of malignancies, primarily low-grade gliomas and acute myeloid leukemia. We report a medicinal chemistry campaign around a 7,7-dimethyl-7,8-dihydro-2H-1λ2-quinoline-2,5(6H)-dione screening hit against the R132H and R132C mutant forms of isocitrate dehydrogenase (IDH1). Systematic SAR efforts produced a series of potent pyrid-2-one mIDH1 inhibitors, including the atropisomer (+)-119 (NCATS-SM5637, NSC 791985). In an engineered mIDH1-U87-xenograft mouse model, after a single oral dose of 30 mg/kg, 16 h post dose, between 16 and 48 h, (+)-119 showed higher tumoral concentrations that corresponded to lower 2-HG concentrations, when compared with the approved drug AG-120 (ivosidenib).

THIAZOLE DERIVATIVES USEFUL AS MUTANT IDH1 INHIBITORS FOR TREATING CANCER

A compound of Formula II or a pharmaceutically acceptable salt thereof, wherein CyN is a cyclic amine group bound via a nitrogen atom; X is C or N; R1 and R2 are each independently a halogen, CN, CF3, CHF2, CH2F, a C1-C10alkyl group, a C1-C10alkoxy group, a di(C1-C5alkyl)amino; m and n are each independently 1, 2, or 3, and represents either a single bond or a double bond, wherein the racemic mixture of 3-(4-(4-chlorophenyl)thiazol-2-yl)-1-(2-ethyl-5-methoxyphenyl)-6-(2-methylprop-1-en-1-yl)-5-(piperazine-1-carbonyl)pyridin-2(1H)-one atropisomers is excluded.

MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER

Compounds of Formula I and Formula II and the pharmaceutically acceptable salts thereof are disclosed The variables A, B, Y, Z, X1, X2, R1-4 and R13-18 are disclosed herein. The compounds are useful for treating cancer disorders, especially those involving mutant IDH1 enzymes. Pharmaceutical compositions containing compounds of Formula I or Formula II and methods of treatment comprising administering compounds of Formula I and Formula II are also disclosed.

COMPOUNDS AND METHODS for the inhibition of HDAC

Disclosed are compounds having the formula: wherein X1, X2, X3, R1, R2, R3, R4, Y, A, Z, L and n are as defined herein, and methods of making and using the same.

Synthesis of novel 3-(1,3-thiazol-2-yl)-7,8-dihydroquinoline-2,5(1H,6H)- diones

An efficient method for the synthesis of novel 3-(1,3-thiazol-2-yl)-7,8- dihydroquinoline-2,5(1H,6H)-diones from various 2- dimethylaminomethylidenecyclohexane-1,3-diones, (1,3-thiazol-2-yl)acetonitriles, and dimethylformamide dimethyl acetal was developed. These transformations proceeded through intermediate 2-[2-(4-aryl-1,3-thiazol-2-yl)-2-cyanoethenyl]-3- oxocyclohex-1-en-1-olates. They were isolated as piperidinium salts and used in further heterocyclization reactions with aromatic amines, giving novel 1-aryl-3-(1,3-thiazol-2-yl)-7,8-dihydroquinoline-2,5(1H,6H)-diones. These compounds were also obtained by preparative three-step "one pot" synthesis under controlled microwave irradiation.

DERIVATIVES OF CHROMEN-2-ONE AS INHIBITORS OF VEGF PRODUCTION IN MAMMALIAN CELLS

The compounds of formula (I) wherein A and R1-R5 are as defined in the description, are inhibitors of Vascular Endothelial Growth Factor and are useful as angiogenesis inhibitors and antiproliferative agents.

AZOLE METHYLIDENE CYANIDE DERIVATIVES AND THEIR USE AS PROTEIN KINASE MODULATORS

The present invention is related to azole derivatives notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such azole derivatives. Said azole derivatives are modulators of the protein kinase signalling pathways, particularly the one involving c-Jun N-terminal kinase and/or Glycogen Kinase Synthase 3. The present invention is furthermore related to novel azole derivatives as well as to methods of their preparation. X is O, S or NR0, with R0 being H or an unsubstituted or substituted C1 -C6 alkyl; A is 2-pyridyl, 3-pyridyl, 4-pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or triazinyl group.

Synthesis of Some Coumarin Derivatives as Potential Laser Dyes

With a view to extend the tunability range and maximum output of the coumarin series of dyes, fifteen new 3-substituted 7-hydroxycoumarins emitting in the blue-green region of the visible spectrum are synthesized, and some of them showed laser activity.